A ging and inactivity are associated with significant changes in cardiovascular physiology. Previous studies by our group has shown that aged heart becomes smaller, stiffer, and less distensible. 1,2 Extreme inactivity also recapitulates a similar cardiac phenotype as observed during spaceflight or prolonged bed rest. 3, 4 In contrast, habitual exercise training results in above average measures of peak Vo 2 adjusted for age and sex, larger stroke volume, increased cardiac mass, and improved measures of ventricular compliance. 5,6
abnormalities, and it forms the basis for our current study investigating the effects of a sedentary lifestyle and aging on cardiac structure and function. We hypothesized that the accumulation of myocardial triglycerides increases with age and sedentariness, and it would be associated with ventricular stiffening and impairments in diastolic function in nonobese and nondiabetic individuals.
Methods

Study Recruitment
Study subjects were recruited from the Dallas Heart Study, a population-based cohort of >6000 individuals, enriched by a random sampling of employees of Texas Health Resources, a large healthcare provider in the Dallas-Fort Worth metroplex, as previously described. 19 Subjects were also recruited prospectively from the Aerobic Center Longitudinal Database at the Cooper Clinic in Dallas, a cohort of individuals with extensively recorded exercise histories for 25 years. All study procedures were approved by the Institutional Review Boards of the University of Texas Southwestern Medical Center at Dallas and Texas Health Resources. After providing informed consent, all subjects underwent testing as outlined below. Volunteers were excluded if they had elevated 24-hour ambulatory blood pressure >140/90 mm Hg. In addition, volunteers were excluded if they were former or current smokers and if they had a history of cardiovascular disease (eg, stroke, myocardial infarction, atrial fibrillation), diabetes mellitus, chronic obstructive pulmonary disease (COPD), and body mass index (BMI) >30 kg/m 2 . All subjects underwent a screening maximal exercise stress echo before enrollment. Subjects were excluded if they had an evidence of coronary ischemia by ECG and echocardiography. Of 353 subjects screened, 191 were excluded for indications listed above. The remaining 162 subjects were predominantly whites (>90%).
Body Composition and Physical Activity Level
Body composition was determined by body density using underwater weights as described previously. 5 Subjects were also given activity monitors (Acitical, Phillips; RT3; and Stayhealthy) that reported total daily activity as METS (metabolic equivalent of task) for 7 days. Total time spent sedentary and active (by METS) were reported in minutes per day. A threshold of 4 METS was used to quantify minutes per day spent in fitness-related activities.
Exercise Testing
A modified Astrand-Saltin incremental treadmill protocol was used to determine peak exercise capacity. Measures of ventilatory gas exchange were made by use of the Douglas bag technique. 5 Gas fractions were analyzed by mass spectrometry (Marquette MGA 1100), and ventilatory volume was measured by a Tissot spirometer. Maximum oxygen uptake was defined as the highest oxygen uptake measured from ≥40 s Douglas bag. To normalize for differences in sex and age, predicted peak Vo 2 values were calculated adjusting for age and sex, as previously reported. 20
Cardiac MRI
All subjects underwent cardiac MRI to assess cardiac morphometric parameters in addition to myocardial triglyceride content. Subjects did not undergo MRI if they had cochlear implants or were claustrophobic. Images were obtained using a 1.5-tesla Gyroscan INTERA whole-body system (Philips Medical Systems, Best, The Netherlands) equipped with spectroscopy and cardiac packages. LV end-diastolic volumes (EDVs) and mass were measured as previously reported using a steady-state-free precision imaging sequence. 21 Tissue triglyceride content was measured using 1 H nuclear MR spectroscopy and quantified as a percentage of water content in a region of interest located in the midventricular septum. During acquisition of spectroscopic data, patients breathed freely. The spectroscopic signal was acquired with cardiac triggering at end systole and respiratory gating at end expiration. A Point-RESolved Spectroscopy (PRESS) sequence was used for spatial localization, and the interpulse delay was defined by the length of a respiratory cycle. NUTS software (Acorn NMR, Fremont, CA) was used to process data. The areas under the signals from water and methylenes of fatty acids in triglycerides were quantified by a line-fitting procedure, and the values were corrected for spin-spin relaxation. 17, 22 Intracardiac Pressure-Volume Measurements Right heart catheterizations were performed via an antecubital vein approach as described previously. 5 A 6Fr Swan-Ganz catheter (Edwards Lifesciences) was placed under sterile conditions into the pulmonary artery using fluoroscopic guidance. Subjects were then placed in a lower body negative pressure chamber to decrease LV preload. Recordings of right atrial pressure, pulmonary capillary wedge pressure (PCWP), and LVEDVs using 3-dimensional (3D) echocardiography were made at baseline after 20 minutes of supine rest and again after 5 minutes each of lower body negative pressure of −15 mm Hg followed by −30 mm Hg. In addition, cardiac echocardiography as described below was also performed during each condition. Study participants were then subjected to 2 loading conditions to increase PCWP with rapid normal saline infusion at 15 and 30 mL/kg at flow rates of ≈200 mL/min. Pressure and echocardiographic measurements were made after each infusion. Cardiac output and stroke volume were calculated using a modified acetylene gas rebreathing technique. 23 The diastolic portion of the pressure-volume (PV) curve was constructed using PCWP and corresponding LVEDVs under the experimental unloading and loading conditions. The ventricular stiffness constant was calculated by an exponential curve fit of the enddiastolic PV relationship, as previously described. 24 Echocardiography Echocardiographic images were acquired on an iE33 machine (Philips) and measured offline using Xcelera cardiovascular image management system (Philips). Images were obtained under baseline, lower body negative pressure, and saline loading conditions. Tissue Doppler images were obtained in the apical 4-chamber view by placing a 2-mm sample volume on the septal and lateral mitral annulus. Mitral inflow velocities were also measured in the 4-chamber view by placing a 2-mm pulsed wave sample volume at the tips of the mitral leaflet during valve opening. Propagation velocity (Vp) was obtained by color M-mode imaging with a sampling area extending from the mid portion of the left atrium to the apex and measuring the slope of the early diastolic aliasing velocity. Isovolumic relaxation time was measured as the time between aortic valve closure and mitral valve opening by placing a 4-mm sample within the LV outflow tract from a 5-chamber view. LV volumes under different loading conditions were determined by offline 3D reconstruction (QLab, version 9.0; Phillips).
Statistical Analysis
Statistical analysis was performed using commercially available software (SPSS, Sigmaplot version 12.0). All reported variables are presented as mean with SD. After dividing the subjects into quintiles by cardiac lipid content, the distribution of majority of variables was skewed. A nonparametric Jonckheere-Terpstra test was therefore used to determine the effect of increasing ranked quintiles of lipid content on measured variables. Pearson correlation of clinical variables with cardiac lipid was performed, and multiple linear regression modeling was then used to determine the clinical variables that best predicted myocardial lipid content. Regression analysis was also performed on echocardiographic and MRI variables. A 2-way repeatedmeasures ANOVA was used to identify the differences in pressure and volume parameters under varying loading conditions between the lowest and highest quintiles of cardiac lipid content. To adjust the cardiac lipid quintile comparisons for age and fitness-related differences in cardiac function, hemodynamic, echocardiographic, and morphometric parameters were modeled using age, sex, and peak Vo 2 as covariates in ANCOVA models. Data transformations were used to meet parametric analysis assumptions as necessary. A P value <0.05 was considered statistically significant.
Results
Baseline Characteristics
Cardiac lipid content was available in 153 of 162 enrolled subjects who had no contraindications to MRI. In the 9 volunteers who did not have lipid measures, 5 had technically limited scans because of motion artifact or excessive heart rate variability, 2 had contaminated signal from epicardial fat, and 2 had levels below detection limits. The mean age of all subjects was 62 years, ranging from 26 to 86 years with an interquartile range of 61 and 69 years. Subjects were stratified by lipid content into quintiles. Lipid content ranged from 0.31±0.10% in the lowest quintile to 1.61±0.62% in the highest quintile (Table 1; Figure 1 ). Subjects in the highest quintiles had larger BMI compared with those in the lowest quintile in addition to higher body fat composition. There were no differences in HgbA1c% or age between groups. As comparison, myocardial 1 H nuclear MR spectroscopy from a previously published study by our group showed a range for triglycerides of 0.46±0.30% in lean (BMI<25 kg/m 2 ) individuals to 1.06±0.62% in subjects with type 2 diabetes mellitus. 22
Clinical Predictors of Cardiac Steatosis
In general, fitness and daily activity levels decreased with increasing quintiles of cardiac lipid content. Subjects in the highest quintile had the lowest measured peak Vo 2 (Figure 2 ). The distribution of peak Vo 2 was large and likely driven by differences in age, body weight, and fitness levels across all subjects. To adjust for the wide distribution and to distinguish whether the relationship between cardiac lipid content and fitness was because of age-and sex-related differences, peak Vo 2 was calculated as a percentage of age-and sex-predicted Vo 2 scaled to ideal body weight. There was a trend toward higher percent predicted peak Vo 2 for subjects with the lowest cardiac lipid content (Jonckheere-Terpstra test, P=0.06). There was also an association between increasing lipid content and daily activity level. Subjects in the lower quintiles were more likely to spend additional minutes per day engaged in activities >4
METS (Table 1) . There was no difference in the amount of time spent sedentary between groups.
Simple linear regression of clinical characteristics and cardiac lipid content across all 153 subjects showed an association among BMI, body fat, peak Vo 2 , % of predicted peak Vo 2 , and minutes per day spent in activities >4 METS ( Table I in the online-only Data Supplement). In our multiple regression models, peak Vo 2 and BMI were significant variables in predicting lipid content (β=−0.02; 95% confidence interval, −0.03 to −0.009 and β=+0.03; 95% confidence interval, 0.001-0.06, respectively; R 2 =0.14; P<0.001). To better understand the association between peak Vo 2 and cardiac lipid content and to account for confounding factors (age, sex, and BMI) that influence peak Vo 2 which may not have been fully adjusted for, the multiple regression model was rerun using percent predicted peak Vo 2 instead of measured peak Vo 2 . In this model, percent-predicted Vo 2 (β=−0.47; 95% confidence interval, −0.82 to −0.12) and age (β=0.013; 95% confidence interval, 0.005-0.021) were the most significant variables (R 2 =0.15; P<0.001) that predicted cardiac lipid content, suggesting that even relative fitness, when adjusted for sex-and age-expected values, remained determinative of intramyocardial lipids.
Effects of Cardiac Lipid Content on Cardiac Structure and Function
MRI was used to assess baseline cardiac structure and function. With increasing quintiles of cardiac lipid, LV end-diastolic and stroke volumes indexed to BSA decreased, whereas LV ejection fraction slightly increased ( Table 2 ). There was no correlation to BSA-indexed LV mass (Jonckheere-Terpstra, P=0.07) or end-systolic volumes.
Hemodynamic and Echocardiographic Parameters
There was no correlation between cardiac lipid content and ventricular stiffness derived from the end-diastolic portion of the PV curve. Stiffness constants derived from PV curves drawn using group-averaged values for indexed EDV and PCWP were similar between subjects with low and high cardiac lipids (Figure 3) . Interestingly, the PV curve for the highest Under baseline conditions, subjects with the highest level of cardiac lipid content had lower peak early mitral annular velocity (tissue Doppler E′ lateral wall velocity) and higher late diastolic mitral inflow (A wave), in addition to lower E/A ratios compared with those with lower levels ( Table 2 ). There were no differences in measures of ventricular relaxation as assessed by isovolumic relaxation time or mitral inflow propagation velocity. The association between decreasing peak early mitral annular velocity and cardiac lipid content remained consistent with increasing ventricular loading conditions. Similarly, the association between increasing late diastolic mitral inflow and cardiac lipid content also persisted across loading conditions (Table 3) .
To determine the independent effects of cardiac lipid content on echocardiographic and morphometric parameters, ANCOVA analysis using cardiac lipid quintiles and defined covariates of age, BMI, and peak Vo 2 was performed. Once adjusted for these covariates, many of the observed relationships were attenuated, and they were no longer statistically significant. Nearly all the interactions were highly nonsignificant (much greater than P=0. 25) , and they did not contribute meaningful information to the model. Therefore, our final model does not include interaction terms. There were no differences by ANCOVA among quintiles with regard to mitral annular tissue Doppler, mitral inflow velocities, or filling pressures. Indexed EDV was also no longer significantly different across lipid quintiles, suggesting that the differences in distensibility seen in Figure 3 were likely reflective of the differences in age and peak fitness levels among the groups.
Discussion
The primary findings of this current study are (1) myocardial steatosis can vary greatly across metabolically healthy individuals and can approach or exceed levels previously reported in patients with diabetes mellitus and metabolic syndrome; (2) clinical predictors of cardiac steatosis included BMI and peak Vo 2 ; however, these associations ceded to age after adjusting peak Vo 2 for age and sex; and (3) myocardial steatosis was associated with decreased ventricular distensibility and markers of early diastolic dysfunction.
Adiposity and the Heart
Myocardial steatosis is a compelling means of bridging the connection between metabolic disorders and associated abnormalities in diastolic function, which in turn could form the basis for the increased incidence of heart failure observed in patients with obesity-related disorders. Although frequently associated with comorbid conditions of coronary artery disease, hypertension and renal dysfunction, patients with diabetes mellitus and who are obese are twice as likely to develop heart failure compared with lean controls even after adjusting for baseline differences in covariates. 25, 26 Advances in nuclear magnetic resonance spectroscopy have opened insight into changes in myocardial composition in patients with metabolic disorders independent of ischemia and ventricular hypertrophy. This concept of metabolic remodeling has focused primarily on the presence of intracardiac triglyceride accumulation as a surrogate marker of a lipotoxic heart. Whether myocardial triglycerides are direct mediators of abnormal cardiac function or represent a biomarker of altered cardiac metabolism remains a key question. The presence of intramyocardial fat has been correlated previously with decreased ventricular strain rates, increased LV mass, and decreased early peak mitral inflow velocity in small studies of individuals with diabetes mellitus and individuals who are obese, suggesting that cardiac lipid content has adverse effects on myocardial structure, leading to diastolic dysfunction and raising the possibility of a therapeutic target to reverse diastolic abnormalities. However the confounding impact of diabetes mellitus and obesity on measures of cardiac function can be difficult to distinguish from the independent effects of intracardiac triglycerides. Diabetes mellitus is known to cause alterations in myocardial calcium signaling and endothelial dysfunction, factors that are difficult to assess clinically. 27 Measuring the effects of cardiac steatosis on myocardial structure and function in metabolically healthy individuals reduces potential confounders, and it may help to elucidate a clearer causal correlation. The findings of our study provide insight into the changes in ventricular function with increasing levels of cardiac lipid content and suggest a plausible causal mechanism, linking the effects of aging, aerobic fitness, and total body adiposity on cardiac function.
Fitness, Aging, and Adiposity
To date, no studies have analyzed the impact of physical activity on cardiac steatosis. Previous studies have shown that metabolic syndrome, visceral adiposity, and impaired glucose tolerance are important clinical predictors of myocardial steatosis. 22, 28 The accumulation of triglycerides in metabolically active tissues, particularly muscle, further decreases the response to insulin-mediated glucose uptake. In contrast, metabolic changes associated with increasing fitness are essentially the antithesis of changes that occur in A indicates peak late mitral inflow velocity; E, peak early mitral inflow velocity; IVRT, isovolumic relaxation time; LVEDV, left ventricular end-diastolic volumes; LVEDVi, LVEDV indexed to BSA; LVEF, LV ejection fraction; LVMi, LV mass BSA indexed; LVSV, LV stroke volume; LVSVi, LVSV BSA indexed; TDI A′ lateral, A′ lateral wall velocity; TDI E′ lateral, tissue Doppler E′ lateral wall velocity; TDI S′ lateral, S′ lateral wall velocity; and Vp, mitral inflow propagation velocity. *P<0.05; †P<0.01; and ‡P<0.001 (Jonckheere-Terpstra trend across increasing quintiles). metabolic syndrome and include improved insulin sensitivity and decreased total body adiposity. 29 Individuals with better fitness would be expected to have improved markers of metabolic health, but because of the colinearity of many variables associated with peak Vo 2 , it is difficult to distinguish the independent effects of 1 clinical factor compared with others. Individuals with high aerobic fitness are more likely to be younger, and they have low BMI and body fat percentage. In a regression model, the correlation between aerobic fitness (peak Vo 2 ) and myocardial triglycerides was more strongly associated than BMI or body fat percentage, suggesting that peak Vo 2 was likely the primary driving factor. Age also was an important factor in the development of cardiac steatosis. Even after scaling for age-and sex-predicted Vo 2 , age remained significantly associated with cardiac lipid content. Both low aerobic fitness and advanced age can be associated with impaired insulin sensitivity, and although not directly measured in our study, these associations may mirror similar metabolic changes and development of cardiac steatosis seen in subjects who are obese or subjects with diabetes mellitus. As individuals age or become more sedentary, the heart is likely not spared from the metabolic milieu of increased body adiposity and BMI. The accumulation of myocardial fat with aging, decreasing aerobic fitness, and increasing BMI, thus, may represent a metabolic change in organ function, eventually leading to the development of increased ventricular diastolic stiffening or prolonged myocardial relaxation times.
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Adiposity and Cardiac Function
Myocardial lipid accumulation was associated with premature markers of abnormal diastolic function. Subjects with the highest quintiles of cardiac lipid content were more likely to have abnormalities in early diastolic myocardial relaxation, lower E/A mitral inflow ratios, smaller indexed EDV, and decreased LV distensibility. These observations were consistent with expected changes in cardiac function based on clinical predictors of intramyocardial triglyceride accumulation (poor aerobic fitness, advanced age). After adjusting for covariates of age, peak Vo 2 , and BMI, the association between myocardial fat and diastolic function was attenuated. Although aging and low cardiovascular fitness share similar diastolic phenotypes, the causal connection leading to diastolic abnormalities shared between these 2 discrete conditions is unknown. The accumulation of cardiac lipid could provide a plausible mechanism for the increased observation of diastolic dysfunction in older or unfit individuals, and it may have deleterious consequences beyond acting just as a biomarker for impaired total body metabolic homeostasis. Preclinical work has shown that lipotoxicity leads to increased production of reactive oxygen species and apoptosis. 30 Prolonged or accelerated accumulation of toxic metabolites could be a key mediator in the decline in diastolic function with age and poor fitness. Although our study did not show an increase in LV stiffness using invasive measures with lipid accumulation, subtle changes in diastolic function may be the precursors, leading to the development of more significant diastolic abnormalities and symptoms of heart failure.
Several questions remain about the consequences of excess cardiac fat content in individuals with concomitant metabolic and cardiac comorbidities. Because the prevalence of diabetes mellitus and obesity continues to rise, there is a greater need to better characterize the consequences of excess adiposity on cardiovascular physiology. Patients with diabetes mellitus or ventricular hypertrophy may accumulate myocardial lipids at an earlier age and develop the metabolic phenotype of an older and sedentary heart. Whether these metabolic changes are pathological remains unanswered, and other studies have even raised the possibility of a beneficial effect of obesity in heart failure, a concept termed the obesity paradox. 31 Future studies may help to answer these questions by the use of agents to lower myocardial triglyceride content in conjunction with a comprehensive assessment of myocardial function. In addition, long-term prospective studies of cardiac fat content and the development of diastolic abnormalities and heart failure may also be helpful in establishing a causal connection. A indicates peak late mitral inflow velocity; CI, confidence interval; E, peak early mitral inflow velocity; LBNP, lower body negative pressure; NS, normal saline rapid infusion; TDI A′ lateral, A′ lateral wall velocity; and TDI E′ lateral, tissue Doppler E′ lateral wall velocity.
Limitations
Our study is limited by incomplete characterization of the metabolic profile of participants. Both visceral fat and insulin sensitivity have been correlated previously to myocardial triglyceride content, but they were not measured in our current study. 22, 28 Fasting glucose was also unavailable. The majority of our subjects were elderly with only 25% of participants <60 years. This may have underestimated the association between age and cardiac lipid content, given that younger subjects tended to have lower cardiac lipid content.
Overall, we think that our study provides further insight to the cardiac metabolic adaptations that develop with aging and sedentariness. Our findings suggest that lipid content in a healthy population is more widely distributed than those previously reported, and the accumulation of myocardial lipids is associated with low aerobic fitness, increased BMI, and advanced age. Decreased ventricular distensibility and early markers of diastolic abnormalities were seen with increasing levels of myocardial triglyceride, suggesting that myocardial fatty acid metabolism may be a viable therapeutic target in improving cardiac function in diabetic or obese patients.
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